Format

Send to

Choose Destination
Taiwan J Ophthalmol. 2019 Apr-Jun;9(2):136-137. doi: 10.4103/tjo.tjo_10_19.

Reply to comment on: "Advantages of bevacizumab for aggressive posterior retinopathy of prematurity".

Author information

1
Department of Ophthalmology and Visual Science, University of Chicago, 5841 S. Maryland Avenue, MC2114, Chicago, USA.
2
Retina Consultants, Ltd, 2454 E Dempster St, Suite 400, Des Plaines, IL, USA.

Conflict of interest statement

The authors declare that there are no conflicts of interests of this paper.

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center